Back

Is WHO International Standard for Anti-SARS-CoV-2 Immunoglobulin Clinically Useful?

Lukaszuk, K.; Kiewisz, J.; Rozanska, K.; Podolak, A.; Jakiel, G.; Woclawek-Potocka, I.; Lukaszuk, A.; Rabalski, L.

2021-05-02 infectious diseases
10.1101/2021.04.29.21256246
Show abstract

BackgroundThe introduction of vaccination against SARS-CoV-2 infection needs precise instruments for quality control of vaccination procedure, detection of poor immunological response and estimation of the achieved protection against the disease but also against infection and being infective. ObjectiveTo compare new automated SARS-CoV 2 Ig assay performance characteristics from the automated Elecsys SARS-CoV-2 S (Roche) with the new LIAISON(R) SARS-CoV-2 TrimericS IgG (DiaSorin) assay and their compatibility with WHO International Standard for anti-SARS-CoV-2 immunoglobulin. In the context of the mass vaccination programs, we undertook the investigation of clinical utility of the two new automated assays by analyzing results in samples collected at specified time points relative to the vaccination time. DesignProspective assay evaluation. PatientsMedical staff undergoing vaccination with BioNTech/Pfizer Comirnaty vaccine between January and March 2021 (n = 79) and referred for serum antiSARS-CoV 2 Ig testing prior to vaccination, 21 days after the first dose, and 8, 14 and 30 days after the second dose. Main Outcome Measure(s): Serum antibody levels measured with Roche and DiaSorin assays. ResultsIntra-assay imprecision was low with DiaSorin at 3.46%; and Roche at 2.5%. The Passing-Bablok regression equation for all tested samples was y (DiaSorin) = 184.61 + (1.03 x Roche) and the correlation between the assays (r=0.587; p < 0.0001). ConclusionsThe novel automated assays exhibit strong concordance in calibration, with assay-specific interpretation required for routine clinical use. These results highlight the need for further work on the international standard of measurement of SARS-CoV 2 Ig especially in era of vaccination. The serological assays can be useful to detect IgG/IgM antibodies, to assess the degree of immunization, to trace the contacts, and to support the decision to readmit people to work or vaccinate them again. However, the values generated by both assays can be markedly different, and assay-specific and personalized interpretation is required.

Matching journals

The top 13 journals account for 50% of the predicted probability mass.

1
PLOS ONE
based on 1737 papers
Top 54%
8.3%
2
Journal of Virological Methods
based on 20 papers
Top 0.1%
7.6%
3
Diagnostics
based on 36 papers
Top 0.7%
4.5%
4
Clinical Microbiology and Infection
based on 54 papers
Top 0.6%
4.5%
5
Journal of Clinical Virology
based on 54 papers
Top 0.9%
3.0%
6
Clinical Chemistry and Laboratory Medicine (CCLM)
based on 11 papers
Top 0.1%
3.0%
7
International Journal of Infectious Diseases
based on 115 papers
Top 4%
2.8%
8
BMJ Open
based on 553 papers
Top 31%
2.8%
9
Journal of Clinical Microbiology
based on 77 papers
Top 2%
2.8%
10
Journal of Medical Virology
based on 95 papers
Top 3%
2.8%
11
Infectious Diseases and Therapy
based on 18 papers
Top 0.2%
2.8%
12
Frontiers in Medicine
based on 99 papers
Top 7%
2.5%
13
Vaccine
based on 140 papers
Top 3%
2.5%
50% of probability mass above
14
Journal of Infection
based on 64 papers
Top 2%
2.4%
15
Clinical Infectious Diseases
based on 219 papers
Top 12%
2.3%
16
Eurosurveillance
based on 77 papers
Top 3%
2.3%
17
Viruses
based on 79 papers
Top 2%
2.3%
18
Microbiology Spectrum
based on 86 papers
Top 1%
1.8%
19
Scientific Reports
based on 701 papers
Top 72%
1.6%
20
Vaccines
based on 131 papers
Top 3%
1.6%
21
Diagnostic Microbiology and Infectious Disease
based on 15 papers
Top 0.2%
1.6%
22
Infectious Diseases
based on 15 papers
Top 0.3%
1.6%
23
Frontiers in Immunology
based on 140 papers
Top 5%
1.3%
24
Clinical Chemistry
based on 14 papers
Top 1.0%
1.3%
25
European Journal of Clinical Microbiology & Infectious Diseases
based on 14 papers
Top 0.6%
1.3%
26
Journal of Clinical Medicine
based on 77 papers
Top 12%
1.3%
27
BMC Infectious Diseases
based on 110 papers
Top 14%
1.2%
28
eBioMedicine
based on 82 papers
Top 5%
1.2%
29
Journal of Clinical Virology Plus
based on 10 papers
Top 0.1%
1.2%
30
Frontiers in Public Health
based on 135 papers
Top 25%
0.8%